Robert Oldham says pharmacogenomics and current FDA rules aren’t compatible
Robert Oldham is CEO of Cancer Therapeutics of Augusta, Ga. He was previously director of oncology at Vanderbilt University Medical Center and director of the Biological Response Modifiers Program at the National Cancer Institute. He has published more than 400 articles and 13 books in the scientific literature. He can be reached at [email protected]ring.com.